Treeline Biosciences has now raised a total of around $473 million in funding.

Treeline Biosciences, a cancer biotechnology startup led by biotech executives and Co-Founders Joshua Bilenker (CEO) and Jeffrey Engelman (CSO), has landed a Series A funding of $262 million to further its research pipeline. Bilenker, who had previously worked a stint in the oncology division of the FDA, went on to found a biotech company called Loxo Oncology which was later acquired by Eli Lilly (NYSE: LLY) for $8 billion in 2019. (BIO PHARMA DIVE)

The funding was led by KKR’s Health Care Strategic Growth Fund II, a fund dedicated to investing in high-growth health care-related companies. Other investors included Rock Springs Capital, ARCH Venture Partners, GV, OrbiMed, Access Industries, funds and accounts advised by T. Rowe Price Associates, Inc., Ajax Health/Zeus, Casdin Capital and Aisling Capital.

“While we’ve made significant progress in building the pipeline we envisioned at company formation, we are a team that wants our data to do the talking,” said the founders in an announcement on the firm’s website. “We are excited for the day when we provide scientific disclosure that has clear implications for patients with cancer and other serious diseases. That day is not today.”

The company, known to be very low-profile, said it had appointed around 130 people at its various locations, though it chooses not to reveal too much about its work.

Related Story: Nested Therapeutics Raises $90M Series ‘A’ Led By Goldman Sachs Asset Management